Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.

[1]  R. Fisher,et al.  Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck , 2008 .

[2]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.

[3]  J. Buatti,et al.  Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. , 2007, International journal of radiation oncology, biology, physics.

[4]  A. Scott,et al.  Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. , 2007, Seminars in nuclear medicine.

[5]  R. Fisher,et al.  Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. , 2007, International journal of radiation oncology, biology, physics.

[6]  J. Pignon,et al.  Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. , 2007, International journal of radiation oncology, biology, physics.

[7]  Suzanne L Wolden,et al.  A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. , 2006, International journal of radiation oncology, biology, physics.

[8]  David L. Schwartz,et al.  Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer , 2006, Clinical Cancer Research.

[9]  T. Ward,et al.  Hypoxia in head and neck cancer. , 2006, The British journal of radiology.

[10]  M. Gillison,et al.  Clinical implications of human papillomavirus in head and neck cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Fisher,et al.  Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Nehmeh,et al.  An iterative technique for lesion segmentation in PET images , 2006 .

[13]  Margie Hunt,et al.  Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. , 2006, International journal of radiation oncology, biology, physics.

[14]  D. Brizel,et al.  Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Lester J. Peters,et al.  Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  K. Soo,et al.  Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison , 2005, British Journal of Cancer.

[17]  C Clifton Ling,et al.  Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor mo , 2005, International journal of radiation oncology, biology, physics.

[18]  M. Gillison,et al.  Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. , 2004, Seminars in oncology.

[19]  D. Rischin,et al.  Strategies to overcome accelerated repopulation and hypoxia--what have we learned from clinical trials? , 2004, Seminars in oncology.

[20]  D. Lowy,et al.  A causal role for human papillomavirus in head and neck cancer , 2004, The Lancet.

[21]  A. Garden,et al.  Management of nonsinonasal neuroendocrine carcinomas of the head and neck , 2003, Cancer.

[22]  O. S. Nielsen,et al.  Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  Johan Bussink,et al.  Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  K. Harrington,et al.  In regard to Lee et al., IJROBP 2002;53:630-637. , 2003, International Journal of Radiation Oncology, Biology, Physics.

[25]  M Alber,et al.  On biologically conformal boost dose optimization. , 2003, Physics in medicine and biology.

[26]  Johan Bussink,et al.  Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. , 2002, Cancer research.

[27]  R. Wahl,et al.  PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  K. Shah,et al.  Human papillomavirus–associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers , 2001, Current opinion in oncology.

[29]  R. Fisher,et al.  Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Overgaard,et al.  A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  D. Sidransky,et al.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.

[32]  J. Bourhis,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.

[33]  D. Dunlop,et al.  Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  W. Koch,et al.  Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? , 1999, Current opinion in oncology.

[35]  S. Spencer,et al.  Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. , 1998, International journal of radiation oncology, biology, physics.

[36]  C Weigel,et al.  Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. , 1998, International journal of radiation oncology, biology, physics.

[37]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[38]  M. Nordsmark.  Direct measurements of tumor-tissue pO2. A way of selecting patients for hyperoxic treatment. , 1996, Strahlentherapie und Onkologie (Print).

[39]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[40]  G L Rosner,et al.  Pretreatment oxygenation profiles of human soft tissue sarcomas. , 1994, International journal of radiation oncology, biology, physics.

[41]  B. Marples,et al.  The effect of radiosensitizers on the survival response of hypoxic mammalian cells: the low X-ray dose region, hypersensitivity and induced radioresistance. , 1994, Radiation research.

[42]  M. Dorie,et al.  Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. , 1993, Cancer research.

[43]  S. Macphail,et al.  Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin. , 1991, International journal of radiation oncology, biology, physics.

[44]  R. Durand,et al.  The response of hypoxic cells in SCCVII murine tumors to treatment with cisplatin and x rays. , 1991, International journal of radiation oncology, biology, physics.

[45]  M. Korbelik,et al.  Inactivation of hypoxic cells by cisplatin and radiation at clinically relevant doses. , 1989, Radiation research.

[46]  E. Douple,et al.  Platinum complexes as radiosensitizers of hypoxic mammalian cells. , 1978, The British journal of cancer. Supplement.

[47]  D. Hykes,et al.  Radiation-induced DNA damage and lethality in E. coli as modified by the antitumor agent cis-dichlorodiammineplatinum (II). , 1977, Radiation research.

[48]  Sadek Nehmeh,et al.  Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. , 2008, International journal of radiation oncology, biology, physics.

[49]  Gig Mageras,et al.  Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. , 2008, International journal of radiation oncology, biology, physics.

[50]  S. Apisarnthanarax,et al.  Current Imaging Paradigms in Radiation Oncology , 2005, Radiation research.

[51]  R. Fisher,et al.  Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  M. W. D. Dvm.  Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome , 1998 .

[53]  S. Senan,et al.  Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  Brown,et al.  Hypoxia-Specific Cytotoxins in Cancer Therapy. , 1996, Seminars in radiation oncology.

[55]  J. Brown,et al.  Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. , 1994, International journal of radiation oncology, biology, physics.

[56]  P Vaupel,et al.  Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[57]  E. Hall,et al.  Radiobiology for the radiologist , 1973 .